Jun Li1,2, Megan S Rice3, Tianyi Huang1,4, Susan E Hankinson2,4,5, Charles V Clevenger6, Frank B Hu1,2,4, Shelley S Tworoger7,8,9. 1. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 3. Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 5. Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA. 6. Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA. 7. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Shelley.Tworoger@moffitt.org. 8. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Shelley.Tworoger@moffitt.org. 9. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Inc., 12902 Magnolia Drive, MRC-CANCONT, Tampa, FL, 33612-9497, USA. Shelley.Tworoger@moffitt.org.
Abstract
AIMS/HYPOTHESIS: Prolactin, a multifunctional hormone, is involved in regulating insulin sensitivity and glucose homeostasis in experimental studies. However, whether circulating concentrations of prolactin are associated with risk of type 2 diabetes remains uncertain. METHODS: We analysed the prospective relationship between circulating prolactin concentrations and type 2 diabetes risk in the Nurses' Health Study (NHS) and NHSII with up to 22 years of follow-up. Total plasma prolactin was measured using immunoassay in 8615 women free of type 2 diabetes and cardiovascular disease at baseline blood collection (NHS 1989-1990; NHSII 1996-1999) and a subset of 998 NHS women providing a second blood sample during 2000-2002. Baseline bioactive prolactin was measured in a subset of 2478 women using the Nb2 bioassay. HRs were estimated using Cox regression. RESULTS: A total of 699 incident type 2 diabetes cases were documented during 156,140 person-years of follow-up. Total plasma prolactin levels were inversely associated with type 2 diabetes risk; the multivariable HR comparing the highest with the lowest quartile was 0.73 (95% CI 0.55, 0.95; ptrend = 0.02). The associations were similar by menopausal status and other risk factors (pinteraction > 0.70). Additional adjustment for sex and growth hormones, adiponectin, and inflammatory and insulin markers did not significantly alter the results. The association of plasma bioactive prolactin with type 2 diabetes risk was non-significantly stronger than that of total prolactin (HR comparing extreme quartiles, 0.53 vs 0.81 among the subset of 2478 women, pdifference = 0.11). The inverse association of total prolactin with type 2 diabetes was significant during the first 9 years after blood draw but waned linearly with time, whereas for bioactive prolactin, the inverse relationship persisted for a longer follow-up time after blood draw. CONCLUSIONS/ INTERPRETATION: A normally high circulating total prolactin concentration was associated with a lower type 2 diabetes risk within 9-10 years of follow-up since blood draw in US women. Our findings are consistent with experimental evidence, suggesting that among healthy women, prolactin within the biologically normal range may play a protective role in the pathogenesis of type 2 diabetes.
AIMS/HYPOTHESIS: Prolactin, a multifunctional hormone, is involved in regulating insulin sensitivity and glucose homeostasis in experimental studies. However, whether circulating concentrations of prolactin are associated with risk of type 2 diabetes remains uncertain. METHODS: We analysed the prospective relationship between circulating prolactin concentrations and type 2 diabetes risk in the Nurses' Health Study (NHS) and NHSII with up to 22 years of follow-up. Total plasma prolactin was measured using immunoassay in 8615 women free of type 2 diabetes and cardiovascular disease at baseline blood collection (NHS 1989-1990; NHSII 1996-1999) and a subset of 998 NHS women providing a second blood sample during 2000-2002. Baseline bioactive prolactin was measured in a subset of 2478 women using the Nb2 bioassay. HRs were estimated using Cox regression. RESULTS: A total of 699 incident type 2 diabetes cases were documented during 156,140 person-years of follow-up. Total plasma prolactin levels were inversely associated with type 2 diabetes risk; the multivariable HR comparing the highest with the lowest quartile was 0.73 (95% CI 0.55, 0.95; ptrend = 0.02). The associations were similar by menopausal status and other risk factors (pinteraction > 0.70). Additional adjustment for sex and growth hormones, adiponectin, and inflammatory and insulin markers did not significantly alter the results. The association of plasma bioactive prolactin with type 2 diabetes risk was non-significantly stronger than that of total prolactin (HR comparing extreme quartiles, 0.53 vs 0.81 among the subset of 2478 women, pdifference = 0.11). The inverse association of total prolactin with type 2 diabetes was significant during the first 9 years after blood draw but waned linearly with time, whereas for bioactive prolactin, the inverse relationship persisted for a longer follow-up time after blood draw. CONCLUSIONS/ INTERPRETATION: A normally high circulating total prolactin concentration was associated with a lower type 2 diabetes risk within 9-10 years of follow-up since blood draw in US women. Our findings are consistent with experimental evidence, suggesting that among healthy women, prolactin within the biologically normal range may play a protective role in the pathogenesis of type 2 diabetes.
Entities:
Keywords:
Hormone; Insulin; Prolactin; Type 2 diabetes
Authors: Shelley S Tworoger; A Heather Eliassen; Bernard Rosner; Patrick Sluss; Susan E Hankinson Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Kate E Therkelsen; Tobin M Abraham; Alison Pedley; Joseph M Massaro; Patrice Sutherland; Udo Hoffmann; Caroline S Fox Journal: J Am Heart Assoc Date: 2016-02-23 Impact factor: 5.501
Authors: Antonio J Ponce; Tomás Galván-Salas; Ricardo M Lerma-Alvarado; Xarubet Ruiz-Herrera; Tomás Hernández-Cortés; Rodrigo Valencia-Jiménez; Laura E Cárdenas-Rodríguez; Gonzalo Martínez de la Escalera; Carmen Clapp; Yazmín Macotela Journal: Endocrine Date: 2020-01-09 Impact factor: 3.633
Authors: Ziyi Zhang; Anthony L Piro; Amina Allalou; Stacey E Alexeeff; Feihan F Dai; Erica P Gunderson; Michael B Wheeler Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Jun Li; Dong Hoon Lee; Jie Hu; Fred K Tabung; Yanping Li; Shilpa N Bhupathiraju; Eric B Rimm; Kathryn M Rexrode; JoAnn E Manson; Walter C Willett; Edward L Giovannucci; Frank B Hu Journal: J Am Coll Cardiol Date: 2020-11-10 Impact factor: 24.094
Authors: Marta Guasch-Ferré; Gang Liu; Yanping Li; Laura Sampson; JoAnn E Manson; Jordi Salas-Salvadó; Miguel A Martínez-González; Meir J Stampfer; Walter C Willett; Qi Sun; Frank B Hu Journal: J Am Coll Cardiol Date: 2020-03-05 Impact factor: 24.094
Authors: Eric B Rimm; Qi Sun; Jun Li; Yanping Li; Kerry L Ivey; Dong D Wang; Jeremy E Wilkinson; Adrian Franke; Kyu Ha Lee; Andrew Chan; Curtis Huttenhower; Frank B Hu Journal: Gut Date: 2021-04-29 Impact factor: 23.059
Authors: Cassandra A Hathaway; Megan S Rice; Mary K Townsend; Susan E Hankinson; Alan A Arslan; Julie E Buring; Göran Hallmans; Annika Idahl; Laura D Kubzansky; I-Min Lee; Eva A Lundin; Patrick M Sluss; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254